+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Increased frequency of complete remission by lenograstim recombinant human granulocyte colony-stimulating factor administration after intensive induction chemotherapy in elderly patients with De Novo acute myeloid leukemia Final results of a randomized multicenter double-blind controlled study



Increased frequency of complete remission by lenograstim recombinant human granulocyte colony-stimulating factor administration after intensive induction chemotherapy in elderly patients with De Novo acute myeloid leukemia Final results of a randomized multicenter double-blind controlled study



Blood 84(10 Suppl. 1): 231A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 031886526

Download citation: RISBibTeXText


Related references

European multicentre phase III randomized placebo-controlled study of lenograstim recombinant glycosylated human granulocyte colony stimulating factor in elderly patients with de novo acute myeloid leukemia. British Journal of Haematology 87(Suppl. 1): 154, 1994

A randomized double-blind controlled study of recombinant human granulocyte colony-stimulating factor in patients with neutropenia induced by consolidation chemotherapy for acute myeloid leukemia. (rG.CSF clinical study group). Japanese Journal of Clinical Hematology 36(6): 606-614, 1995

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109(12): 5129-5135, 2007

Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpatient resource utilization. Journal of the National Cancer Institute. Monographs 1995(19): 37-40, 1995

Prophylactic use of granulocyte colony-stimulating factor after induction chemotherapy in patients with newly diagnosed acute myeloid leukemia may increase the complete remission rate: a meta-analysis of five randomised controlled trials. Leukemia and Lymphoma 50(3): 457-459, 2009

Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77(4): 700-711, 1991

Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia. International Journal of Hematology 71(2): 136-143, 2000

Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study. Annals of Hematology 82(11): 677-683, 2003

Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia A randomized, placebo-controlled, double blind, safety and efficacy study. Blood 98(11 Part 1): 799a, 2001

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 106(1): 27-34, 2005

A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 83(8): 2086-2092, 1994

Granulocyte-macrophage colony-stimulating factor to increase efficacy of intensive sequential chemotherapy with mitoxantrone , etoposide and cytarabine in previously treated acute myeloid leukemia A multicenter randomized placebo-controlled trial. Blood 90(10 Suppl. 1 Part 1): 505A, 1997

The Efficacy and Safety of DA-3030 (Recombinant Human Granulocyte Colony-Stimulating Factor) in Neutropenia after the Remission Induction Chemotherapy in Patients with Acute Myelogenous Leukemia. Cancer Research and Treatment 35(1): 66-68, 2003

A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). Blood 91(8): 2722-2730, 1998

Concomitant administration of granulocyte colony-stimulating factor and induction chemotherapy of adult acute lymphoblastic leukemia First results of a multicenter, open-label, phase III study in randomized parallel groups. Blood 84(10 Suppl. 1): 231A, 1994